Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling

OncoImmunology

Volumn 5, Issue 8, 2016, Pages

  Sun, Danfeng ^a,b   Lin, Yanwei ^a,b   Hong, Jie ^b   Chen, Haoyan ^b   Nagarsheth, Nisha ^a   Peng, Dongjun ^a   Wei, Shuang ^a   Huang, Emina ^c   Fang, Jingyuan ^b   Kryczek, Ilona ^a   Zou, Weiping ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Colon cancer; IL 22; PRC2; STAT3; Th22

Indexed keywords

CYCLINE; INTERLEUKIN 22; LENTIVIRUS VECTOR; POLYCOMB REPRESSIVE COMPLEX 2; SHORT HAIRPIN RNA; STAT3 PROTEIN;

ARTICLE; CANCER CONTROL; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLON CARCINOGENESIS; CONTROLLED STUDY; FLOW CYTOMETRY; HISTONE METHYLATION; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TH22 CELL; THYMIDINE INCORPORATION ASSAY; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84983752667     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1082704     Document Type: Article

References (29)

1. J.Deng, Y.Liu, H.Lee, A.Herrmann, W.Zhang, C.Zhang, S.Shen, S.J.Priceman, M.Kujawski, S.K.Pal et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell 2012; 21:642-54; PMID:22624714; http://dx.doi.org/10.1016/j.ccr.2012.03.039
2. H.Spits, J.P.Di Santo. The expanding family of innate lymphoid cells:regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011; 12:21-7; PMID:21113163; http://dx.doi.org/10.1038/ni.1962
3. R.Basu, D.B.O'Quinn, D.J.Silberger, T.R.Schoeb, L.Fouser, W.J.Ouyang, R.D.Hatton, C.T.Weaver. Th22 Cells Are an Important Source of IL-22 for Host Protection against Enteropathogenic Bacteria. Immunity 2012; 37:1061-75; PMID:23200827; http://dx.doi.org/10.1016/j.immuni.2012.08.024
4. K.Song, Y.J.Nam, X.Luo, X.Qi, W.Tan, G.N.Huang, A.Acharya, C.L.Smith, M.D.Tallquist, E.G.Neilson et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012; 485:599-604; PMID:22660318; http://dx.doi.org/10.1038/nature11139
5. I.Kryczek, Y.Lin, N.Nagarsheth, D.Peng, L.Zhao, E.Zhao, L.Vatan, W.Szeliga, Y.Dou, S.Owens et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 2014; 40:772-84; PMID:24816405; http://dx.doi.org/10.1016/j.immuni.2014.03.010
6. L.Z.Yu, H.Y.Wang, S.P.Yang, Z.P.Yuan, F.Y.Xu, C.Sun, R.H.Shi. Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World J Gastroenterol 2013; 19:2638-49; PMID:23674871; http://dx.doi.org/10.3748/wjg.v19.i17.2638
7. R.Jiang, H.Wang, L.Deng, J.Hou, R.Shi, M.Yao, Y.Gao, A.Yao, X.Wang, L.Yu et al. IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer 2013; 13:59; PMID:23379788; http://dx.doi.org/10.1186/1471-2407-13-59
8. A.Andoh, Z.Zhang, O.Inatomi, S.Fujino, Y.Deguchi, Y.Araki, T.Tsujikawa, K.Kitoh, S.Kim-Mitsuyama, A.Takayanagi et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005; 129:969-84; PMID:16143135; http://dx.doi.org/10.1053/j.gastro.2005.06.071
9. K.Wolk, S.Kunz, E.Witte, M.Friedrich, K.Asadullah, R.Sabat. IL-22 increases the innate immunity of tissues. Immunity 2004; 21:241-54; PMID:15308104; http://dx.doi.org/10.1016/j.immuni.2004.07.007
10. S.J.Aujla, Y.R.Chan, M.Zheng, M.Fei, D.J.Askew, D.A.Pociask, T.A.Reinhart, F.McAllister, J.Edeal, K.Gaus, S.Husain et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008; 14:275-81; PMID:18264110; http://dx.doi.org/10.1038/nm1710
11. Y.Zheng, P.A.Valdez, D.M.Danilenko, Y.Hu, S.M.Sa, Q.Gong, A.R.Abbas, Z.Modrusan, N.Ghilardi, F.J.de Sauvage et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008; 14:282-9; PMID:18264109; http://dx.doi.org/10.1038/nm1720
12. G.Pickert, C.Neufert, M.Leppkes, Y.Zheng, N.Wittkopf, M.Warntjen, H.A.Lehr, S.Hirth, B.Weigmann, S.Wirtz et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009; 206:1465-72; PMID:19564350; http://dx.doi.org/10.1084/jem.20082683
13. A.Barski, S.Cuddapah, K.Cui, T.Y.Roh, D.E.Schones, Z.Wang, G.Wei, I.Chepelev, K.Zhao. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129:823-37; PMID:17512414; http://dx.doi.org/10.1016/j.cell.2007.05.009.
14. S.Varambally, S.M.Dhanasekaran, M.Zhou, T.R.Barrette, C.Kumar-Sinha, M.G.Sanda, D.Ghosh, K.J.Pienta, R.G.Sewalt, A.P.Otte et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9; PMID:12374981; http://dx.doi.org/10.1038/nature01075
15. C.G.Kleer, Q.Cao, S.Varambally, R.Shen, I.Ota, S.A.Tomlins, D.Ghosh, R.G.Sewalt, A.P.Otte, D.F.Hayes et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100:11606-11; PMID:14500907; http://dx.doi.org/10.1073/pnas.1933744100
16. K.Mimori, K.Ogawa, M.Okamoto, T.Sudo, H.Inoue, M.Mori. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 2005; 31:376-80; PMID:15837043; http://dx.doi.org/10.1016/j.ejso.2004.11.001
17. R.Cao, Y.Zhang. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14:155-64; PMID:15196462; http://dx.doi.org/10.1016/j.gde.2004.02.001
18. A.Subramanian, H.Kuehn, J.Gould, P.Tamayo, J.P.Mesirov. GSEA-P:a desktop application for Gene Set Enrichment Analysis. Bioinformatics 2007; 23:3251-3; PMID:17644558; http://dx.doi.org/10.1093/bioinformatics/btm369
19. W.Yu, E.J.Chory, A.K.Wernimont, W.Tempel, A.Scopton, A.Federation, J.J.Marineau, J.Qi, D.Barsyte-Lovejoy, J.Yi et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012; 3:1288; PMID:23250418; http://dx.doi.org/10.1038/ncomms2304
20. M.Kamanaka, S.Huber, L.A.Zenewicz, N.Gagliani, C.Rathinam, W.O'Connor, Jr., Y.Y.Wan, S.Nakae, Y.Iwakura, L.Hao et al. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med 2011; 208:1027-40; PMID:21518800; http://dx.doi.org/10.1084/jem.20102149
21. S.Huber, N.Gagliani, L.A.Zenewicz, F.J.Huber, L.Bosurgi, B.Hu, M.Hedl, W.Zhang, W.O'Connor, Jr., A.J.Murphy et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012; 491:259-63; PMID:23075849; http://dx.doi.org/10.1038/nature11535
22. R.Jiang, Z.Tan, L.Deng, Y.Chen, Y.Xia, Y.Gao, X.Wang, B.Sun. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54:900-9; PMID:21674558; http://dx.doi.org/10.1002/hep.24486
23. W.Zhang, Y.Chen, H.Wei, C.Zheng, R.Sun, J.Zhang, Z.Tian. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 2008; 14:6432-9; PMID:18927282; http://dx.doi.org/10.1158/1078-0432.CCR-07-4401
24. K.Kim, G.Kim, J.Y.Kim, H.J.Yun, S.C.Lim, H.S.Choi. Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation. Carcinogenesis 2014; 35:1352-61; PMID:24517997; http://dx.doi.org/10.1093/carcin/bgu044
25. Y.H.Huang, Y.F.Cao, Z.Y.Jiang, S.Zhang, F.Gao. Th22 cell accumulation is associated with colorectal cancer development. World J Gastroenterol 2015; 21:4216-24; PMID:25892871; http://dx.doi.org/10.3748/wjg.v21.i14.4216
26. C.J.Kim, A.Nazli, O.L.Rojas, D.Chege, Z.Alidina, S.Huibner, S.Mujib, E.Benko, C.Kovacs, L.Y.Shin et al. A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis. Mucosal Immunol 2012; 5:670-80; PMID:22854709; http://dx.doi.org/10.1038/mi.2012.72
27. S.Nishikawa, D.L.Dewi, H.Ishii, M.Konno, N.Haraguchi, Y.Kano, T.Fukusumi, K.Ohta, Y.Noguchi, M.Ozaki et al. Transcriptomic study of dormant gastrointestinal cancer stem cells. Int J Oncol 2012; 41:979-84; PMID:22735680.
28. Y.W.Lin, L.L.Ren, H.Xiong, W.Du, Y.N.Yu, T.T.Sun, Y.R.Weng, Z.H.Wang, J.L.Wang, Y.C.Wang et al. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer. J Pathol 2013; 230:277-90; PMID:23424038; http://dx.doi.org/10.1002/path.4179
29. T.X.Cui, I.Kryczek, L.Zhao, E.Zhao, R.Kuick, M.H.Roh, L.Vatan, W.Szeliga, Y.Mao, D.G.Thomas et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 2013; 39:611-21; PMID:24012420; http://dx.doi.org/10.1016/j.immuni.2013.08.025